Key facts
- It has raised $103.7M; the latest was Accelerator/Incubator in Feb 2025.
- Notable investors include Swedish-American Chamber of Commerce - New York (SACCNY), AMF Tjänstepension, Fjärde AP-fonden, RoosGruppen, Alto Cumulus Asset Management — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for SmartCella
- ·The full record, as it builds
Funding rounds
No funding rounds for SmartCella are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SmartCella
Developer of cell therapy solutions designed to deliver treatments safely and effectively. The company offers localized administration of cells, drugs, RNA, and other therapies, enabling the healthcare industry to develop new treatments for various medical conditions.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2014
- Employees
- 64
- Website
- smartcella.com/
- Ownership
- Privately Held (backing)
SmartCella doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SmartCella shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SmartCella in its N-PORT filings yet. We sweep new filings monthly.